Resona Asset Management Co. Ltd. Sells 2,901 Shares of Natera, Inc. $NTRA

Resona Asset Management Co. Ltd. reduced its stake in shares of Natera, Inc. (NASDAQ:NTRA) by 7.1% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 37,684 shares of the medical research company’s stock after selling 2,901 shares during the period. Resona Asset Management Co. Ltd.’s holdings in Natera were worth $8,646,000 at the end of the most recent quarter.

Several other institutional investors also recently bought and sold shares of NTRA. Integrated Wealth Concepts LLC raised its holdings in Natera by 6.6% during the first quarter. Integrated Wealth Concepts LLC now owns 1,560 shares of the medical research company’s stock valued at $221,000 after buying an additional 96 shares in the last quarter. NewEdge Advisors LLC raised its holdings in Natera by 68.3% during the first quarter. NewEdge Advisors LLC now owns 4,552 shares of the medical research company’s stock valued at $644,000 after buying an additional 1,847 shares in the last quarter. Focus Partners Wealth raised its holdings in Natera by 8.6% during the first quarter. Focus Partners Wealth now owns 5,993 shares of the medical research company’s stock valued at $847,000 after buying an additional 474 shares in the last quarter. Sivia Capital Partners LLC bought a new position in Natera during the second quarter valued at about $298,000. Finally, WINTON GROUP Ltd bought a new position in Natera during the second quarter valued at about $558,000. 99.90% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In other Natera news, insider Solomon Moshkevich sold 3,405 shares of Natera stock in a transaction that occurred on Friday, May 1st. The stock was sold at an average price of $203.69, for a total transaction of $693,564.45. Following the sale, the insider directly owned 142,295 shares of the company’s stock, valued at approximately $28,984,068.55. The trade was a 2.34% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider John Fesko sold 291 shares of Natera stock in a transaction that occurred on Friday, May 1st. The shares were sold at an average price of $206.16, for a total value of $59,992.56. Following the sale, the insider directly owned 187,220 shares in the company, valued at $38,597,275.20. The trade was a 0.16% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold a total of 38,266 shares of company stock valued at $7,747,808 over the last ninety days. Company insiders own 5.63% of the company’s stock.

Natera Trading Down 0.6%

NASDAQ NTRA opened at $203.69 on Friday. The stock’s 50 day moving average is $200.78 and its two-hundred day moving average is $215.41. The company has a market capitalization of $29.17 billion, a price-to-earnings ratio of -124.96 and a beta of 1.57. Natera, Inc. has a 1-year low of $131.81 and a 1-year high of $256.36.

Natera (NASDAQ:NTRA) last released its quarterly earnings data on Thursday, February 26th. The medical research company reported $0.35 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.46) by $0.81. The company had revenue of $665.50 million for the quarter, compared to the consensus estimate of $600.68 million. Natera had a negative return on equity of 14.74% and a negative net margin of 9.05%.During the same period in the previous year, the business earned ($0.41) earnings per share. On average, analysts predict that Natera, Inc. will post -1.49 earnings per share for the current year.

Analyst Upgrades and Downgrades

NTRA has been the topic of several recent research reports. Morgan Stanley cut their target price on Natera from $265.00 to $250.00 and set an “overweight” rating on the stock in a report on Tuesday, March 3rd. Wall Street Zen downgraded Natera from a “buy” rating to a “hold” rating in a research report on Saturday, May 9th. Wells Fargo & Company raised their price target on Natera from $215.00 to $220.00 and gave the company an “equal weight” rating in a research report on Friday, May 8th. BTIG Research lowered their price target on Natera from $260.00 to $250.00 and set a “buy” rating on the stock in a research report on Monday, May 11th. Finally, Piper Sandler reaffirmed an “overweight” rating and issued a $249.00 price target on shares of Natera in a research report on Tuesday, May 12th. One analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $256.60.

Natera Company Profile

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.